Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: The Spanish experience

Haematologica

Volumn 85, Issue 5, 2000, Pages 530-538

  Carreras, Enric ^a,j   Tomás, José Francisco ^b   Sanz, Guillermo ^c   Iriondo, Arturo ^d   Boqué, Concha ^e   López, Javier ^f   Cabrera, Rafael ^g   Sureda, Anna ^h   De Soria, Valle Gómez García ^b   Sierra, Jorge ^a   Sanz, Miguel Angel ^c   Torres, Antonio ⁱ  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL DURAN I REYNALS   (Spain)

^f HOSPITAL RAMÓN Y CAJAL   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Bone marrow transplantation; Chronic myeloid leukemia; Unrelated donor BMT

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; FEMALE; GRAFT FAILURE; GRAFT INFECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; RELAPSE; SCHOOL CHILD; SPAIN; SURGICAL MORTALITY;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; SPAIN; SURVIVAL RATE; TISSUE DONORS;

EID: 12944331416     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Passweg JR, Rowlings PA, Horowitz MM. Related donor bone marrow transplantation for chronic myelogenous leukemia. Hematol Oncol Clin N 1998; 12: 81-92.
2. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087-92.
3. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313:765-71.
4. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994; 330: 820-5.
5. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995; 345:1392-7.
6. Bathia R, Forman SJ. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin N 1998; 12:151-72.
7. Beatty PG, Ash R, Hows JM, McGlave PB. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 1989; 4:287-90.
8. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 543-50.
9. Devergie A, Apperley JF, Labopin M, et al. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 11-9.
10. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Eng J Med 1998; 338: 962-8.
11. Dini G, Lamparelli T, Rondelli R, et al. Unrelated donor marrow transplantation for chronic myelogenous leukaemia. Br J Haematol 1998; 102:544-52.
12. Lamparelli T, Van Lint MT, Gualandi F, et al. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Bone Marrow Transplant 1997; 20: 1057-62.
13. McGlave P. Unrelated donor transplant therapy for chronic myelogenous leukemia. Hematol Oncol Clin N 1998; 12:93-105.
14. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18:295-304.
15. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69:204-17.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Star Assoc 1958; 53: 457-81.
17. Grey RJ. A case of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16:1141-54.
18. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-70.
19. Cox DR. Regression models and life-tables. J Roy Stat Soc[B] 1972; 34:187-220.
20. Dixon WJ, ed. BMDP statistical software manual. 3rd ed. Berkeley: University of California Press; 1992.
21. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med 1993; 119:207-14.
22. Mackinnon S, Hows JM, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18:421-5.
23. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92:3515-20.
24. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83:1980-7.
25. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339:1177-85.
26. Ringden O, Remberger M, Mattsson J, et al. Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. Bone Marrow Transplant 1998; 21:43-9.
27. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation SubCommittee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21:1-7.
28. Sahebi F, Copelan E, Crilley P, et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone Marrow Transplant 1996; 17:685-9.
29. Klein JL, Avalos BR, Belt P, et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17: 479-83.
30. Bertz H, Potthoff K, Mertelsmann R, Finke J. Busulfan/cyclophosphamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19:1169-73.
31. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993; 81:249-53.
32. Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: Influence of HLA A and B incompatibility on outcome. Blood 1995; 86:1636-42.
33. Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87:4455-62.
34. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89:4226-35.
35. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82:2235-8.
36. Motion AJ, Gooley T, Hansen JA, et al. Impact of pretransplant interferon-alpha on outcome of unrelated donor marrow transplants for chronic myeloid leukemia in first chronic phase [abstract]. Blood 1997; 90:536.
37. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85:2981-90.
38. Zuffa E, Bandini G, Bonini A, et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 1998; 83:231-6.